Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB19055 Phase 1 in Healthy Chinese Adults
NCT07254481Phase 1Recruiting
- Sponsor
- Shenzhen Yangli Pharmaceutical Technology Co. Ltd.
- Start
- Oct 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VB19055 in hypertension (HTN) (3 arms), sponsored by Shenzhen Yangli Pharmaceutical Technology Co. Ltd. Primary endpoint: Treatment Emergent Adverse Events. Started Oct 2025; status: recruiting.
02
Drugs
VB19055
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07254481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07254481.